S E Geller1, L Studee. 1. Department of Obstetrics and Gynecology, College of Medicine, University of Illinois, Chicago 60612, USA.
Abstract
INTRODUCTION: Menopause is associated with mid-life, a time when many women begin to experience the signs and symptoms of aging, such as increases in blood pressure, changes in lipid profiles, loss of bone mass density, and diminished memory and cognition. Given the result of the Women's Health Initiative, many women no longer consider hormone therapy the first option for promoting healthy aging. Instead, they are turning to botanical and dietary supplement (BDS) products in place of hormone therapy. This paper reviews the evidence available for use of isoflavones from soy and red clover for the treatment or prevention of these health issues. METHODS: The MEDLINE and EMBASE databases were searched for articles relating to soy or red clover supplement use for prevention and/or treatment of heart disease, hyperlipidemia, osteoporosis, mood disorders and cognitive abilities. Studies were included if they were randomized, controlled trials and included peri- or postmenopausal women. RESULTS: Isoflavone products appear to be the most useful for improving lipid profiles; however, the evidence suggests that isoflavone extracts from soy are less effective than products containing soy protein or red clover isoflavones. Soy protein appears to reduce levels of total cholesterol and low density lipoprotein cholesterol, while red clover reduces levels of triglycerides and increases high density lipoprotein cholesterol. The data were somewhat less convincing, although promising, for increasing bone mass density and improving cognitive abilities. CONCLUSIONS: Research suggests that isoflavones found in soy foods and red clover appear to have a small but positive health effect on plasma lipid concentrations, bone mass density, and cognitive abilities. Given the lack of serious safety concerns in the short term, it would appear that including soy and red clover in the diet of postmenopausal women, not withstanding a soy allergy, might be beneficial.
INTRODUCTION: Menopause is associated with mid-life, a time when many women begin to experience the signs and symptoms of aging, such as increases in blood pressure, changes in lipid profiles, loss of bone mass density, and diminished memory and cognition. Given the result of the Women's Health Initiative, many women no longer consider hormone therapy the first option for promoting healthy aging. Instead, they are turning to botanical and dietary supplement (BDS) products in place of hormone therapy. This paper reviews the evidence available for use of isoflavones from soy and red clover for the treatment or prevention of these health issues. METHODS: The MEDLINE and EMBASE databases were searched for articles relating to soy or red clover supplement use for prevention and/or treatment of heart disease, hyperlipidemia, osteoporosis, mood disorders and cognitive abilities. Studies were included if they were randomized, controlled trials and included peri- or postmenopausal women. RESULTS:Isoflavone products appear to be the most useful for improving lipid profiles; however, the evidence suggests that isoflavone extracts from soy are less effective than products containing soy protein or red cloverisoflavones. Soy protein appears to reduce levels of total cholesterol and low density lipoprotein cholesterol, while red clover reduces levels of triglycerides and increases high density lipoprotein cholesterol. The data were somewhat less convincing, although promising, for increasing bone mass density and improving cognitive abilities. CONCLUSIONS: Research suggests that isoflavones found in soy foods and red clover appear to have a small but positive health effect on plasma lipid concentrations, bone mass density, and cognitive abilities. Given the lack of serious safety concerns in the short term, it would appear that including soy and red clover in the diet of postmenopausal women, not withstanding a soy allergy, might be beneficial.
Authors: T Ohta; S Nakatsugi; K Watanabe; T Kawamori; F Ishikawa; M Morotomi; S Sugie; T Toda; T Sugimura; K Wakabayashi Journal: Carcinogenesis Date: 2000-05 Impact factor: 4.944
Authors: Sheila G West; Kirsten F Hilpert; Vijaya Juturu; Peter L Bordi; Johanna W Lampe; Shaker A Mousa; Penny M Kris-Etherton Journal: J Womens Health (Larchmt) Date: 2005-04 Impact factor: 2.681
Authors: Heather M Engelman; D Lee Alekel; Laura N Hanson; Anumantha G Kanthasamy; Manju B Reddy Journal: Am J Clin Nutr Date: 2005-03 Impact factor: 7.045
Authors: Bahram H Arjmandi; Edralin A Lucas; Dania A Khalil; Latha Devareddy; Brenda J Smith; Jennifer McDonald; Andrea B Arquitt; Mark E Payton; Claudia Mason Journal: Nutr J Date: 2005-02-23 Impact factor: 3.271
Authors: Gonzalo R Malca-Garcia; Daniel Zagal; James Graham; Dejan Nikolić; J Brent Friesen; David C Lankin; Shao-Nong Chen; Guido F Pauli Journal: J Ethnopharmacol Date: 2019-04-11 Impact factor: 4.360
Authors: Stacie E Geller; Lee P Shulman; Richard B van Breemen; Suzanne Banuvar; Ying Zhou; Geena Epstein; Samad Hedayat; Dejan Nikolic; Elizabeth C Krause; Colleen E Piersen; Judy L Bolton; Guido F Pauli; Norman R Farnsworth Journal: Menopause Date: 2009 Nov-Dec Impact factor: 2.953
Authors: Siomara C Monteiro; Cristiane B de Mattos; Juliana Ben; Carlos A Netto; Angela T S Wyse Journal: Metab Brain Dis Date: 2008-07-22 Impact factor: 3.584